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Chronic ethanol-induced downregulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1𝛼) and
upregulation of peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC1𝛽) affect hepatic lipid oxidation and
lipogenesis, respectively, leading to fatty liver injury. Low-𝜔3 fatty acid (Low-𝜔3FA) that primarily regulates PGC1𝛼 and soy protein
(SP) that seems to have its major regulatory effect on PGC1𝛽 were evaluated for their protective effects against ethanol-induced
hepatosteatosis in rats fed with Lieber-deCarli control or ethanol liquid diets with high or low 𝜔3FA fish oil and soy protein. Low𝜔3FA and SP opposed the actions of chronic ethanol by reducing serum and liver lipids with concomitant decreased fatty liver. They
also prevented the downregulation of hepatic Sirtuin 1 (SIRT1) and PGC1𝛼 and their target fatty acid oxidation pathway genes and
attenuated the upregulation of hepatic PGC1𝛽 and sterol regulatory element-binding protein 1c (SREBP1c) and their target lipogenic
pathway genes via the phosphorylation of 5 adenosine monophosphate-activated protein kinase (AMPK). Thus, these two novel
modulators attenuate ethanol-induced hepatosteatosis and consequent liver injury potentially by regulating the two opposing lipid
oxidation and lipogenic pathways.

1. Introduction
Alcohol liver disease is a major cause of morbidity and mortality, affecting millions world-wide [1]. Long-term exposure
of ethanol causes fatty liver disease or hepatosteatosis [2],
which further leads to steatohepatitis, fibrosis, and finally
cirrhosis that may result in death [3]. Hepatosteatosis is
characterized by the accumulation of lipids, triglyceride
and cholesterol, due to an imbalance between hepatic lipid
degradation and synthesis, leading to an enlarged fatty liver
[3]. Studies have shown that alcohol causes the following:
(i) increased mobilization of adipose fat into the liver, due
to increased adipose lipoprotein lipase, (ii) decreased fat
oxidation due to downregulation of fatty acid oxidation
genes, (iii) increased fat synthesis due to upregulation of
lipogenic genes, and (iv) impaired synthesis of apolipoprotein

B and secretion of very low density lipoprotein (VLDL), the
major lipoprotein for the export of hepatic lipids to peripheral
tissues [4].
Transcriptional coactivators peroxisome proliferator receptor coactivator 1 alpha (PGC1𝛼) and peroxisome proliferator receptor coactivator 1 beta (PGC1𝛽) as well as sterol
regulatory element-binding proteins (SREBPs) play vital roles
in regulating the lipid oxidizing and lipogenic genes and
thereby control the progression of hepatosteatosis and the
consequent onset of fibrosis and other forms of liver injury
[5, 6]. Peroxisome proliferator-activated receptors (PPARs)
are members of the nuclear hormone receptor super family
that are ligand-dependent transcription factors. There are
three isotypes, namely, PPAR𝛼, PPAR𝛽, and PPAR𝛾. Whereas
PPAR𝛼 is expressed in all tissues controlling the fatty acid
oxidation pathway genes, PPAR𝛾 is primarily expressed in
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adipose tissue and the liver, regulating the lipogenic pathway
genes. PPAR𝛽 is found in many tissues although mainly in
gut, kidney, and heart [7–9]. It is linked to colon cancer
[10] but has not been well studied. PGC1𝛼 regulates lipid
oxidation pathway genes via PPAR𝛼 and PGC1𝛽 regulates
lipogenic pathway genes via the sterol regulatory elementbinding proteins SREB1a, SREB1c, and SREBP2 [11]. SREB1c
predominantly regulates fatty acid biosynthesis while SREB1a
and SREBP2 control cholesterol synthesis [3]. AMP activated
protein kinase (AMPK) is known to be activated by phosphorylation to form phosphorylated AMPK (pAMPK), which, in
turn, phosphorylates and inactivates acetyl CoA carboxylase
(ACC) and the rate-limiting enzyme of lipogenesis [4, 12, 13].
PGC1𝛼 is controlled by silence regulator gene 1 (SIRT1),
the eukaryotic equivalent of SIR2 gene in prokaryotes, and
histone acetyltransferases (HAT) [14]. SIRT1 activates PGC1𝛼
by deacetylation while HAT inactivates PGC1𝛼 by acetylation
[15]. On the other hand, SIRT1 destabilizes SREBP1c by
deacetylation while HAT stabilizes SREBP1c by acetylation
[16]. PGC1𝛽 is upregulated by dietary saturated fat and
coactivates SREBP1c and liver X receptor (LXR) families
of transcription factors leading to increased lipogenesis,
lipoprotein transport, and VLDL secretion [17, 18]. Therefore,
any modulator that can either activate PGC1𝛼 via the interplay between SIRT1 and histone acetyltransferase (HAT) or
inactivate PGC1𝛽/SREBP1c should be beneficial in preventing alcoholic hepatosteatosis and consequent liver injury.
Omega-3/6 fatty acids are polyunsaturated fatty acids
(PUFA) obtained from fish and plant sources. The most
common omega-3 PUFA are eicosapentaenoic acid (EPA),
docosahexaenoic acid (DHA), and alpha-linolenic acid
(ALA). Whereas algae and oils from fish such as salmon,
mackerel, and herring are rich in EPA and DHA, ALA is
found in vegetable oils such as canola, flax seed oil, soybean
oil, and nuts such as walnuts [19]. Soy proteins (SP) are found
in soybean legume containing all 8 essential amino acids and
very low saturated fat [20]. In recent times, both omega-3
PUFA and SP have received increased attention due to their
beneficial effects against cardiovascular disease, obesity, type
2 diabetes, and certain cancers, among others [19, 21, 22]. Low
omega 3 fatty acids (low-𝜔3FA) are known to have lipid lowering effects in humans [23] while SP lowers plasma and liver
cholesterol and triglycerides in both animals and humans
[24]. Studies have shown that SP prevents hyperinsulinemia
and reduces the expression of LXRs and SREBP1c mRNAs
in obese Zucker rat model [25–27]. However, the molecular
mechanisms by which these dietary modulators can control
the two transcriptional coactivators are yet to be explored.
In this study, we demonstrate the novel actions of low-𝜔3FA
and SP in inhibiting alcoholic hepatosteatosis by regulating
two opposing vital pathway genes of lipid degradation and
synthesis via PGC1𝛼 and PGC1𝛽, respectively. Therefore,
low-𝜔3FA and SP are potentially potent dietary modulators
that seem to have these profound lipid lowering properties
involving lipid catabolic and anabolic pathways. Moreover,
low-𝜔3FA and SP stimulate AMPK phosphorylation and
block ethanol-induced increased lipogenesis. Thus, this may
be the first time a systematic approach is made to alleviate
alcoholic hepatosteatosis by the combined effects of novel
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natural modulators that promise to intervene with both lipid
oxidizing and lipogenic pathways.

2. Material and Methods
2.1. Animals. Wild-type (WT) female Wistar rats (∼150 g
body weight) from Charles River, Wilmington, MA, were
housed in pairs per cage in plastic cages, in a temperaturecontrolled room, at 25∘ C with 12-hours light-dark cycle. All
animals were fed a pelleted commercial diet (Purina Rodent
Chow, number 500, TMI Nutrition, St. Louis, MO) during
the first week of acclimation period after arrival. Experiments
were performed according to the approved institutional
animal care and use committee protocol. Female rats were
randomly divided into 4 groups of 5 rats each and were pairfed Lieber-DeCarli control or ethanol (EtOH) liquid diets
(36% total fat calories) with high-𝜔3FA (14.1% of calories as
𝜔3FA) or low-𝜔3FA (2.7% of calories as 𝜔3FA) fish oil or
EtOH with SP for 4 weeks.
2.2. Diets. The diets are isocaloric and their formulations are
according to the modified method of Lieber and DeCarli
[28] with the recommended normal nutrients, vitamins, and
minerals according to AIN-93 diet [29]. Thus, 36% of the total
energy of ethanol diet is from fat, 20% from protein, 36% from
EtOH, and the rest from the carbohydrate. The corresponding
isocaloric control diet has isoenergetic amounts of dextrinmaltose in place of EtOH. EtOH concentration in the liquid
diet was gradually increased starting at 1% level on day
1 and reaching the 5% level over a 7-day period to allow
the animals to adapt to EtOH in the diet. These diets are
supplemented with 120 IU of tocopherol/L and 200 mg/L of
tertiary-butyl hydroquinone as antioxidants as per AIN-93
diet recommendations [28, 29].
2.3. Lipid and Lipoprotein Analysis. Blood samples were
collected and centrifuged at 3100 rpm using a Beckman
J6M (Beckman Coulter, Indianapolis, IN) for 10 min at 4∘ C.
Separated serum, plasma, and liver samples were frozen at
−80∘ C until assayed. Liver lipids and high density lipoproteins (HDL) were extracted as previously described [30, 31].
Cholesterol was analyzed using Sigma diagnostic kit number
352 (Sigma-Aldrich, St. Louis, MO) according to the method
of Allain et al. [32] and triglycerides were analyzed using
Sigma diagnostic kit number 339 (Sigma-Aldrich, St. Louis,
MO) according to the method of McGowan et al. [33]. All
protein concentration determinations were done according to
Bradford method [34] with bovine serum albumin (BSA) as
the standard.
2.4. Isolation of Plasma HDL and Its Labeling with [3 H]
Cholesteryl Oleate. HDL was isolated from various pooled
groups of rat plasma according to Gidez et al. [30]. Protein
concentration was determined colorimetrically using bovine
serum albumin (BSA) as a standard [34]. HDL cholesterol
content was measured according to Zlatkis and Zak [35].
HDL labeling with [3 H] cholesteryl oleate was performed
according to Basu et al. [36], and the specific activity is
expressed as dpm/mg HDL cholesterol.
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2.5. Quantification of Hepatosteatosis by Oil Red O. Livers
from various experimental groups were cut into small pieces
and washed immediately with ice cold PBS and mounted on
optimum cutting temperature (OCT) embedding compound
in peel-a-way embedding molds (Electron Microscope Sciences, Hatfield, PA). Liver tissues were cryosectioned and
stained with oil red O to measure accumulation of lipid using
an automated histometric system (Image-Pro Plus 6.1, Media
Cybernetics, Bethesda, MD) as described previously [37]. The
data are expressed as average oil red O percentage area of lipid
staining. Values are means ± SEM.
2.6. RNA Isolation and Real-Time RT-PCR. The total RNA
was isolated from each liver using the Tri-Reagent (Molecular
Research Center, Cincinnati, OH) as manufacturer’s instructions. Isolated total RNA was reverse transcribed by in vitro
transcription as described by the manufacturer (Invitrogen,
Carlsbad, CA). Quantitative real-time PCR was performed
using a Bio-Rad iCycler using the SYBR green PCR mix
(Bio-Rad, Hercules, CA). Typical real-time PCR reaction
mixture included same amount of cDNA templates from RT,
10 pM of each primers, 10 𝜇M of dNTPs, 3 mM of MgCl2 ,
10x buffer, and 2 𝜇 of high fidelity Taq DNA polymerase in
a reaction volume of 50 𝜇L with 0.1x SYBR Green I. The
PCR conditions were 3 min at 95∘ C followed by 40 cycles
at 95∘ C for 30 seconds, 55∘ C for 30 seconds, and 72∘ C for
1 min. Each primer pair was first tested by regular PCR to
be highly effective and specific for amplification. 𝛽-Actin was
used as the standard housekeeping gene. Ratios of specific
mRNA and actin mRNA expression levels were calculated
by subtracting the threshold cycle number (Ct) of the target
gene from the Ct of actin and raising 2 to the power of this
difference. Ct values were defined as the number of PCR
cycles at which the fluorescent signal during the PCR reaches
a fixed threshold. Target gene expressions were expressed
relative to 𝛽-actin expression. The various primer pairs for
indicated rat genes and transcription factors are listed in
Supplemental Table 1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2016/1840513.
2.7. Western Blot Analysis. Liver extracts from each experimental group were diluted into SDS-PAGE sample buffer
[50 mM Tris (pH 6.8), 2% SDS, 10% glycerol, 15 mM 2mercaptoethanol, and 0.25% bromophenol blue] and electrophoretically resolved in Novex (Life Technologies, San
Diego, CA) 4–20% denaturing polyacrylamide gels. Proteins
are electrophoretically transferred to PVDF membrane and
processed for immunodetection using the corresponding
polyclonal primary antibodies for each of the above factors.
After thorough washing, the primary antibody was detected
with horse radish peroxidase conjugated secondary antibody
specific to IgG of the respective primary antibody. Protein
bands were visualized by chemiluminescence and quantified
using FluorChem Imager (Alpha Innotech, CA). The nuclear
extracts from each group were analyzed for the level of SIRT1,
PGC1𝛼, and PGC1𝛽 and the mature form of SREBP1c in the
respective groups using the respective specific antibodies,
while total protein extracts were analyzed for the levels of
ACC, c-Met, AMPK, and pAMPK using respective specific
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antibodies. To determine the levels of acetylated-PGC1𝛼, the
liver nuclear extract from each group was initially immunoprecipitated with anti-PGC1𝛼 followed by immunoblotting
with acetylated lysine antibody. The polyclonal antibodies for
all the above transcription factors were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA), Cayman Chemicals
(Ann Arbor, MI), and UpState Cell Signaling Solutions (Lake
Placid, NY). The specificity of each antibody was verified
before use for the above analyses.
2.8. Immunoprecipitation Analysis. Immunoprecipitation
was performed as previously described [38]. To determine
the levels of acetylated-PGC1𝛼, the liver nuclear extract
from each group was initially immunoprecipitated with
anti-PGC1𝛼 (Abcam, Cambridge, MA), followed by immunoblotting with acetylated lysine antibody (Cell Signaling
Technology, Danvers, MA).
2.9. Statistical Analysis. Experimental data were statistically
analyzed, employing the paired and unpaired “𝑡” tests on the
control and the experimental values. The appropriate data
were analyzed by one-way or two-way analysis of variance
(ANOVA) at 𝑝 < 0.05 followed by Tukey contrast to evaluate
the true correlation between various parameters.

3. Results
3.1. Effects of Chronic Ethanol, Low-𝜔3FA, or SP on Serum
and Liver Lipids and Hepatic Lipid Score. Serum cholesterol
(Figure 1(a)) and triglycerides (Figure 1(b)) were significantly
increased in EtOH group by 1.8-fold (𝑝 < 0.05) and 1.2-fold
(𝑝 < 0.05), respectively, compared to control. Similarly, total
liver cholesterol (Figure 1(c)) and triglycerides (Figure 1(d))
were also markedly increased in EtOH group by 3.9-fold
(𝑝 < 0.05) and 4.1-fold (𝑝 < 0.05), respectively, compared to
control. In contrast, dietary low-𝜔3FA or SP feeding to EtOHfed groups significantly decreased serum and liver cholesterol
and triglycerides to the level closer to that of the control
group. Furthermore, the hepatic accumulation of lipids as
measured by oil red O staining is markedly increased in EtOH
group by 7.5-fold (𝑝 < 0.001) as compared to the control. This
effect is significantly reduced after dietary administration of
low-𝜔3FA and SP in the EtOH-fed group by 93% (𝑝 < 0.05)
and 45% (𝑝 < 0.05), respectively (Figure 1(e)).
3.2. Effects of Low-𝜔3FA and SP on EtOH-Mediated Alterations in the Lipid Oxidation Pathway. Chronic EtOH leads
to a significant decrease in fatty acid oxidation (48.7 ±
5.8 nmoles/g/h, 𝑝 < 0.05) as compared to control (100 ±
8.6 nmoles/g/h). We further investigated whether the mechanisms of action of low-𝜔3FA and SP on EtOH-induced
decrease in fatty acid oxidation are mediated via the regulation of the transcriptional coactivator PGC1𝛼, SIRT1, and
the downstream pathway. Figure 2(a) showed that low-𝜔3FA
and SP treatment restored chronic EtOH-mediated 32% (𝑝 <
0.05) downregulation in SIRT1 mRNA by 85% (𝑝 < 0.05)
and 80% (𝑝 < 0.05), respectively, as compared to EtOH
group. EtOH also significantly downregulated PGC1𝛼 mRNA
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Figure 1: Influence of EtOH, low-𝜔3FA, and SP on (a) total serum cholesterol, (b) serum triglycerides, (c) total liver cholesterol, and (d)
liver triglycerides. Each value is mean ± SD of 3 samples/group. (e) shows the representative medium-power (20x) photomicrographs of liver
sections stained with oil red O as described in Section 2 and the plot of the mean hepatic lipid scores of all samples in each group ± SE of 3
samples/group. ∗ 𝑝 < 0.05 versus control; ∗∗ 𝑝 < 0.05 versus EtOH.

by 40% (𝑝 < 0.05) that was restored to 1.5-fold (𝑝 < 0.05)
and 2-fold (𝑝 < 0.05) over the control level by low-𝜔3FA and
SP treatment, respectively (Figure 2(b)). Additionally, CPT1
mRNA was also markedly downregulated by chronic EtOH
(24%, 𝑝 < 0.05) which was restored to 1.5-fold (𝑝 < 0.05) over
the control level by these dietary modulators (Figure 2(c)).
Similarly, chronic EtOH markedly decreased the nuclear
protein expression of SIRT1 and PGC1𝛼 by 38% (𝑝 < 0.05)
and 35% (𝑝 < 0.05), respectively, which was restored over the

control levels by low-𝜔3FA and SP treatment (Figures 2(d)
and 2(e)). PPAR𝛼, a ligand-activated transcription factor,
involved in the regulation of hepatic fatty acid oxidation
[39], was also evaluated. EtOH significantly decreased PPAR𝛼
protein levels by 50% (𝑝 < 0.05) that was restored by 1.8fold (𝑝 < 0.05) and 1.6-fold (𝑝 < 0.05) by low-𝜔3FA
and SP treatment, respectively (see supplementary materials,
Figure S1). Thus, low-𝜔3FA and SP are effective modulators
in correcting the decreased fatty acid oxidation caused by
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Figure 2: Influence of EtOH, low-𝜔3FA, and SP on lipid oxidation pathway. Total RNA from each animal was reverse transcribed and used in
the qRT-PCR analysis using gene specific primers as described in Section 2 for (a) SIRT1, (b) PGC1𝛼, and (c) CPT1. Each gene was normalized
to 𝛽-actin mRNA. Nuclear protein was extracted from each animal and used for Western Blot analysis using specific antibodies as described in
Section 2 for (d) SIRT1 and (e) PGC1𝛼. Values are means of triplicate experiments ± SD of 3 samples/group and were corrected for difference
in loading after reprobing with an antibody to Lamin B1. ∗ 𝑝 < 0.05 versus control; ∗∗ 𝑝 < 0.05 versus EtOH.

chronic EtOH via the regulation of SIRT1, PGC1𝛼, CPT1, and
PPAR𝛼.
In order to test whether the action of low-𝜔3FA and SP
on hepatic lipid catabolism was mediated through the active
or inactive forms of PGC1𝛼 via the modulation of SIRT1,
we determined the level of acetylated PGC1𝛼 in the liver
tissue of various groups. Figure 3 shows that chronic EtOH
increased the hepatic acetylated (inactive) form of PGC1𝛼 by
40% (𝑝 < 0.05) because of EtOH-mediated decrease in SIRT1
by 38% (𝑝 < 0.05) as compared to the control (Figure 2(d)),
thereby accounting for decreased fatty acid oxidation. In
contrast, low-𝜔3FA and SP decreased the inactive form of
PGC1𝛼 by 37% and 25%, respectively, as compared to EtOH
group (Figure 3) via the upregulation of SIRT1 (Figures 2(a)

and 2(d)), thereby accounting for restoring the decreased
fatty acid caused by chronic EtOH to the control level. Thus,
low-𝜔3FA and SP may lower alcoholic hepatosteatosis by
augmenting the relative levels of active form of PGC1𝛼; that
in turn effectively restored hepatic lipid catabolism that is
impaired by chronic alcohol exposure.
3.3. Effects of Low-𝜔3FA and SP on Chronic EtOH-Mediated
Alterations in the Lipogenic Pathway. Figure 4(a) shows that
chronic EtOH markedly upregulated PGC1𝛽 mRNA level by
52% (𝑝 < 0.05) as compared to the control, and low-𝜔3FA
and SP downregulated the EtOH effect by 61% (𝑝 < 0.05) and
55% (𝑝 < 0.05), respectively. Similarly, Figure 4(b) shows a
marked 50% (𝑝 < 0.05) upregulation in SREBP1c mRNA that
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was reduced to 30% and 50% (𝑝 < 0.02) of the control value
by low-𝜔3FA and SP treatment, respectively. Chronic EtOH
also markedly upregulated the mRNA expression levels of
ACC, which regulates fatty acid synthesis by 2-fold (𝑝 < 0.05)
and this was significantly suppressed by 50% (𝑝 < 0.05) in the
low-𝜔3FA-EtOH group and by 70% (𝑝 < 0.05) in SP-EtOH
group (Figure 4(c)). In contrast, as shown in Figure 4(d),
the mRNA expression levels of c-Met were significantly
downregulated by 35% (𝑝 < 0.05) after chronic EtOH
administration, and low-𝜔3FA and SP treatment significantly
restored EtOH-induced downregulation of c-Met mRNA
level to 86% (𝑝 < 0.05) and 95% (𝑝 < 0.05), of the
control value, respectively. These results were confirmed by
measuring the nuclear or total protein expression of the
above genes relative to those of the corresponding subcellular
marker proteins. Figure 4(e) shows that low-𝜔3FA and SP fed
rats showed suppressed EtOH-mediated increase (60%, 𝑝 <
0.05) in the relative nuclear expression of PGC1𝛽 by 68% (𝑝 <
0.05) and 63% (𝑝 < 0.05), respectively. Similarly, as shown in
Figures 4(f) and 4(g), the relative nuclear protein expressions
of SREBP1c and ACC were also markedly increased in chronic
EtOH group by 30% (𝑝 < 0.05) and 50% (𝑝 < 0.05),
respectively, compared to the control group. Administration
of dietary low-𝜔3FA and SP reversed these EtOH-mediated
effects by decreasing SREBP1c protein expression by 50%
(𝑝 < 0.05) and 56% (𝑝 < 0.05), respectively (Figure 4(f)),
and ACC protein expression by 85% (𝑝 < 0.05) and 60%
(𝑝 < 0.05), respectively (Figure 4(g)). On the other hand,
c-Met expression was decreased in the EtOH group by 25%
(𝑝 < 0.05), which were restored in low-𝜔3FA and SP groups
by 35% (𝑝 < 0.05) and 45% (𝑝 < 0.05), respectively, as
compared to the EtOH group (Figure 4(h)).
Since chronic EtOH increases hepatic ACC activity and
lipogenesis by decreasing the phosphorylation of AMPK
(pAMPK), a known inhibitor of ACC, we tested whether low𝜔3FA or SP can counteract these effects of chronic EtOH by
modulating the phosphorylation status of AMPK. As shown
in Figures 5(a) and 5(b), although the level of total AMPK

was unaffected in all groups, low-𝜔3FA and SP restored the
hepatic level of pAMPK that was decreased by 50% (𝑝 < 0.05)
in EtOH group. This increase in pAMPK could also account
for decreased ACC activity and lipogenesis after low-𝜔3FA or
SP treatment.
These findings are consistent with the ability of low𝜔3FA or SP to (i) inhibit chronic EtOH-induced increase in
lipogenic pathway genes and (ii) restore ethanol-mediated
decreased intracellular transport of hepatic triglycerides to
the blood compartment due to impaired VLDL assembly and
secretion. This would lead to the low-𝜔3FA or SP-mediated
reduction in fatty liver caused by chronic alcohol abuse.

4. Discussion
Our results show that low-𝜔3FA and SP exert their hypolipidemic action by upregulating primarily the lipid oxidizing
genes via SIRT1 and PGC1𝛼 signaling pathway that are suppressed by chronic ethanol and downregulating the lipogenic
pathway genes predominantly via the PGC1𝛽 and SREBP1c
signaling pathway. Our data also support the alternative
possibility that low-𝜔3FA and SP could prevent alcoholinduced activation of ACC activity by phosphorylating it via
pAMPK.
SIRT1 is an NAD-dependent deacetylase (histone deacetylase (HDAC)) that has been linked to many beneficial
effects of cellular processes including gene silencing, insulin
resistance, glucose homeostasis, fatty acid metabolism, and
aging, while HAT catalyses the opposite reaction [40]. Thus,
SIRT1 activates PGC1𝛼 by deacetylation while HAT inactivates PGC1𝛼 by acetylation. On the other hand, SIRT1
destabilizes SREBP1c by deacetylation while HAT stabilizes
SREBP1c by acetylation. You et al. [16] and Lieber et al.
[41] have elegantly shown that both long chain and medium
chain saturated fatty acids in the diet restore the expressions
of SIRT1 and PGC1𝛼 that are downregulated by long chain
polyunsaturated fatty acids (PUFA) in chronic ethanol-fed
animals. However, PPAR𝛾 was unaffected by chronic ethanol.
Previously, Fischer et al. [42] have shown in mice that
ethanol leads to PPAR𝛼 dysfunction resulting in impaired
fatty acid oxidation and consequent onset of fatty liver that
is overcome by a PPAR𝛼 agonist. Similarly, other studies [43,
44] have shown that alcohol-mediated fatty liver and injury
are prevented by PPAR𝛾 agonist presumably by activating cMet and blocking alcohol-mediated induction of TNF𝛼. We
recently showed that compared to high fish oil control liquid
diet, feeding of the same high fish oil liquid diet containing
5% (w/v) ethanol for 8 weeks significantly downregulated
hepatic SIRT1, and PGC1𝛼 with the concomitant decreased
hepatic rate of fatty acid oxidation [37]. Nanji et al. [45],
Ronis et al. [46], and Song et al. [47] have demonstrated that
saturated fatty acids protect against chronic alcohol-induced
liver injury as compared to high levels of polyunsaturated
fatty acids. In addition, Huang et al. [48] demonstrated that
low levels of omega 3 polyunsaturated fatty acids, mainly
docosahexaenoic acid, suppressed ethanol-induced hepatic
steatosis. Similarly, Wada et al. [49] also demonstrated that
low levels of fish oil fed prior to ethanol administration
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Figure 4: Influence of EtOH, low-𝜔3FA, and SP on lipogenic pathway. Total RNA from each animal was reverse transcribed and used in
the qRT-PCR analysis using gene specific primers as described in Section 2 for (a) PGC1𝛽, (b) SREBP1c, (c) ACC, and (d) c-Met. Each gene
was normalized to 𝛽-actin mRNA. Nuclear or total protein was extracted from each animal and used for Western Blot analysis using specific
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prevent acute ethanol-induced fatty liver in mice. In agreement with these studies, the present study shows that dietary
low level of 𝜔3FA (2.7%), but not high level of 𝜔3FA
(14.1%), restores the expression of SIRT1 and PGC1𝛼 that are
downregulated by chronic ethanol. Our results also show that
chronic alcohol exposure upregulates PGC1𝛽, ACC, c-Met,
and SREBP1c. Activation of SREBP1c by ethanol feeding in
rats had been already associated with increased expression of
hepatic lipogenic genes as well as the accumulation of triglyceride in the livers [50]. However, Ki et al. [51], Lu et al. [52],
and Zeng et al. [53] demonstrated that SREBP-1c-mediated
lipogenesis pathway was not affected by ethanol or even
suppressed after chronic ethanol intake in rats. While the
inability of these studies to show chronic ethanol-mediated
upregulation of SREBP-1c-mediated lipogenic pathway may
be due to different dietary fat compositions compared to
the present study, we consistently find that the upregulation
of this pathway with the high-𝜔3FA diet was markedly
attenuated by low-𝜔3FA diet. Thus, it is important to point
out that different dietary conditions, particularly the amount
and the type fat in the diet, do affect SREBP activation
pathway in different ways.
Low-𝜔3FA have an inherent property of attenuating
chronic alcohol-mediated hepatosteatosis by upregulating
PGC1𝛼 and downstream lipid degradation pathways while SP
downregulates PGC1𝛽, SREBP1, and downstream lipid synthetic pathways and by controlling the active/inactive forms
of AMPK. Recently, Phillipson et al. demonstrated the lipid
lowering effects of fish oil rich in 𝜔3FA in humans [23]. However, chronic ethanol-induced liver damage in rats fed a high
fat diet (36% fat calories) was exacerbated [45, 46, 54–56]
with polyunsaturated FA from either vegetable oil (𝜔6 family)
or fish oil (𝜔3 family) as evidenced by increased serum
aspartate aminotransferase and alanine aminotransferase as
well as by histopathology. In this study, fish oil constituted
36% of the total calories in the diet, which amounted to
14.1% of the total dietary calories as 𝜔3FA. In contrast, we

showed [57] that the inclusion of only 2.7% of total dietary
calories as 𝜔3FA resulted in lower plasma and liver lipids
in chronic alcohol-fed animals. Furthermore, the same low
level of dietary 𝜔3FA restored the decreased ApoE content
in HDL. Thus, a low level of 𝜔3FA has beneficial effects [58–
60], whereas a significant increase in 𝜔3FA seems to have a
detrimental effect on the liver [45, 46, 54–56]. It is possible
that increased ethanol consumption in the intragastric model
could have also caused the deleterious effects when PUFArich diet was fed [55]. Significantly, PUFA-containing lecithin
diet was shown to prevent alcohol-induced hepatic fibrosis
in baboons [61]. We showed [57] that low-𝜔3FA caused
decreased VLDL production and serum lipids resulting in
lipid-deficient ApoE, which can be easily sialylated and be
associated with HDL. This would be consistent with the
effects of low-𝜔3FA in reversing ethanol-mediated decrease
in HDL-ApoE. Our previous work [58] also demonstrated
that HDL from low-3FA-fed animals were more efficient in
carrying out reverse cholesterol transport (RCT) function
compared to the control animals regardless of whether the
animals were on alcohol or control diet. We found [62] that
cholesterol uptake by Hep-G2 cells from reconstituted HDL
was stimulated by sphingomyelin (SPM). HDL phospholipid
acyl chain composition is known to influence cholesterol
efflux [63]. We also showed that chronic ethanol preferentially
decreased SPM concentration in HDL of alcoholics leading to
its impaired RCT function [64].
The present study shows that SP downregulated ethanolmediated overexpression of PGC1𝛽, SREBP-1, and its target
lipogenic genes such as ACC (Figure 2), whereas it restored
ethanol-mediated downregulation of SIRT1, PGC1𝛼, and lipid
oxidizing genes such as CPT1 (Figure 4). Overall, our results
suggest that the relative hypolipidemic effects of SP compared
to low-𝜔3FA in regulating alcoholic hepatosteatosis were
more due to alteration in the lipogenic pathway, whereas that
of low-𝜔3FA compared to SP was more due to alteration in
the lipid oxidizing pathway.
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In summary, this study has demonstrated the following.
(1) Low-𝜔3FA and SP reduced alcoholic hyperlipidemia as
well as hepatic lipid accumulation as evidenced by decreased
liver cholesterol and triglycerides as well as hepatic histological lipid scores. (2) Low-𝜔3FA and SP prevented alcoholmediated downregulation of SIRT1 and PGC1𝛼 and their
target fatty acid oxidation pathway genes. (3) Low-𝜔3FA
and SP attenuated alcohol-mediated upregulation of PGC1𝛽,
SREBP1c, and its target lipogenic pathway genes. (4) Low𝜔3FA and SP decreased the liver nuclear SREBP1c level
that was increased by chronic ethanol treatment. (5) Low𝜔3FA and SP restored the hepatic level of pAMPK that was
decreased by chronic alcohol treatment.
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5. Conclusion
Unlike high dietary 𝜔3FA, low dietary 𝜔3FA protects against
chronic alcohol-induced liver injury. We have demonstrated that low-𝜔3FA and SP could potentially upregulate
SIRT1/PGC1𝛼 and downregulate PGC1𝛽/SREBP1c signaling
pathways in alleviating alcoholic hepatosteatosis and liver
injury. Thus, our study opens this field to explore other new
therapeutic agents targeted on PGC1𝛼 and PGC1𝛽 pathways
for protection against not only alcoholic liver diseases but
also metabolic syndrome and obesity, the major world-wide
health problems, especially when superimposed in alcohol
abusers.
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